Early clinical trials of Toca 511 and Toca FC show a promising novel treatment for recurrent malignant glioma

References

• Adamson C, Kanu OO, Mehta AI, et al. Glioblastoma multiforme: a review of where we have been and where we are going. Expert Opin Investig Drugs. 2009 Aug;18(8):1061–1083. PubMed PMID: 19555299.
   PubMed Web of Science ®Google Scholar
• Kang JH, Adamson C. Novel chemotherapeutics and other therapies for treating high-grade glioma. Expert Opin Investig Drugs. 2015;24(10):1361–1379. PubMed PMID: 26289791.
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van Den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005 Mar 10;352(10):987–996. PubMed PMID: 15758009.
   PubMed Web of Science ®Google Scholar
• Babu R, Komisarow JM, Agarwal VJ, et al. Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival. J Neurosurg. 2016 Apr;124(4):998–1007. PubMed PMID: 26452121.
   PubMed Web of Science ®Google Scholar
• Li J, Di C, Mattox AK, et al. The future role of personalized medicine in the treatment of glioblastoma multiforme. Pharmgenomics Pers Med. 2010;3:111–127. PubMed PMID: 23226047; PubMed Central PMCID: PMCPMC3513213.
   PubMedGoogle Scholar
• Babu R, Adamson DC. Fluorescence-guided malignant glioma resections. Curr Drug Discov Technol. 2012 Dec;9(4):256–267. PubMed PMID: 22339071.
   PubMedGoogle Scholar
• Halani SH, Adamson DC. Clinical utility of 5-aminolevulinic acid HCl to better visualize and more completely remove gliomas. Onco Targets Ther. 2016;9:5629–5642. PubMed PMID: 27672334; PubMed Central PMCID: PMCPMC5026178.
   PubMed Web of Science ®Google Scholar
• de Groot JF, Mandel JJ. Update on anti-angiogenic treatment for malignant gliomas. Curr Oncol Rep. 2014 Apr;16(4):380. PubMed PMID: 24510742.
   PubMed Web of Science ®Google Scholar
• Wick W, Gorlia T, Bendszus M, et al. Lomustine and bevacizumab in progressive glioblastoma. N Engl J Med. 2017 Nov 16;377(20):1954–1963. PubMed PMID: 29141164.
   PubMed Web of Science ®Google Scholar
• Weller M, Cloughesy T, Perry JR, et al. Standards of care for treatment of recurrent glioblastoma–are we there yet? Neuro Oncol. 2013 Jan;15(1):4–27. PubMed PMID: 23136223; PubMed Central PMCID: PMCPMC3534423.
   PubMed Web of Science ®Google Scholar
• Lee SY. Temozolomide resistance in glioblastoma multiforme. Genes Dis. 2016 September 01;3(3):198–210.
   PubMed Web of Science ®Google Scholar
• Taal W, Oosterkamp HM, Am W, et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol. 2014 Aug;15(9):943–953. PubMed PMID: 25035291.
   PubMed Web of Science ®Google Scholar
• Erdem-Eraslan L, van Den Bent MJ, Hoogstrate Y, et al. Identification of patients with recurrent glioblastoma who may benefit from combined bevacizumab and CCNU therapy: A report from the BELOB trial. Cancer Res. 2016 Feb 1;76(3):525–534. PubMed PMID: 26762204.
   PubMed Web of Science ®Google Scholar
• Burger MC, Mildenberger IC, Wagner M, et al. Bevacizumab for patients with recurrent gliomas presenting with a gliomatosis cerebri growth pattern. Int J Mol Sci. 2017 Mar 29;18(4). PubMed PMID: 28353668; PubMed Central PMCID: PMCPMC5412312.
   Web of Science ®Google Scholar
• Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009 Oct 1;27(28):4733–4740. PubMed PMID: 19720927.
   PubMed Web of Science ®Google Scholar
• Dalba C, Klatzmann D, Logg CR, et al. Beyond oncolytic virotherapy: replication-competent retrovirus vectors for selective and stable transduction of tumors. Curr Gene Ther. 2005 Dec;5(6):655–667. PubMed PMID: 16457654.
   PubMed Web of Science ®Google Scholar
• Naik S, Russell SJ. Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways. Expert Opin Biol Ther. 2009 Sep;9(9):1163–1176. PubMed PMID: 19637971.
   PubMed Web of Science ®Google Scholar
• Ostertag D, Amundson KK, Lopez Espinoza F, et al. Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector. Neuro Oncol. 2012 Feb;14(2):145–159. PubMed PMID: 22070930; PubMed Central PMCID: PMCPMC3266384.
   PubMed Web of Science ®Google Scholar
• Vokes EE. Fluorouracil modulation in head and neck cancer. Adv Exp Med Biol. 1993;339: 197–208. discussion 219–21. PubMed PMID: 7513934.
   PubMedGoogle Scholar
• Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003 May;3(5):330–338. PubMed PMID: 12724731.
   PubMed Web of Science ®Google Scholar
• Pardini B, Kumar R, Naccarati A, et al. 5-Fluorouracil-based chemotherapy for colorectal cancer and MTHFR/MTRR genotypes. Br J Clin Pharmacol. 2011 Jul;72(1):162–163. PubMed PMID: 21204909; PubMed Central PMCID: PMCPMC3141199.
   PubMed Web of Science ®Google Scholar
• Perez OD, Logg CR, Hiraoka K, et al. Design and selection of Toca 511 for clinical use: modified retroviral replicating vector with improved stability and gene expression. Mol Ther. 2012 Sep;20(9):1689–1698. PubMed PMID: 22547150; PubMed Central PMCID: PMCPMC3437576.
   PubMed Web of Science ®Google Scholar
• Mitchell LA, Lopez Espinoza F, Mendoza D, et al. Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable antitumor immunity in a mouse glioma model. Neuro Oncol. 2017 Jul 1;19(7):930–939. PubMed PMID: 28387849; PubMed Central PMCID: PMCPMC5570153.
   PubMed Web of Science ®Google Scholar
• Vincent J, Mignot G, Chalmin F, et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 2010 Apr 15;70(8):3052–3061. PubMed PMID: 20388795.
   PubMed Web of Science ®Google Scholar
• Hiraoka K, Inagaki A, Kato Y, et al. Retroviral replicating vector-mediated gene therapy achieves long-term control of tumor recurrence and leads to durable anticancer immunity. Neuro Oncol. 2017 Jul 1;19(7):918–929. PubMed PMID: 28387831; PubMed Central PMCID: PMCPMC5574670.
   PubMed Web of Science ®Google Scholar
• Heimberger AB, Kong LY, Abou-Ghazal M, et al. The role of tregs in human glioma patients and their inhibition with a novel STAT-3 inhibitor. Clin Neurosurg. 2009;56:98–106. PubMed PMID: 20214040.
   PubMedGoogle Scholar
• Gustafson MP, Lin Y, New KC, et al. Systemic immune suppression in glioblastoma: the interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone. Neuro. 2010 Jul;12(7):631–644. PubMed PMID: 20179016; PubMed Central PMCID: PMCPMC2940665.
   Google Scholar
• Tai CK, Wang WJ, Chen TC, et al. Single-shot, multicycle suicide gene therapy by replication-competent retrovirus vectors achieves long-term survival benefit in experimental glioma. Mol Ther. 2005 Nov;12(5):842–851. PubMed PMID: 16257382.
   PubMed Web of Science ®Google Scholar
• Fisher JF, Sobel JD, Kauffman CA, et al. Candida urinary tract infections–treatment. Clin Infect Dis. 2011 May;52 Suppl 6:S457–S466. PubMed PMID: 21498839.
   PubMed Web of Science ®Google Scholar
• Vermes A, Guchelaar HJ, Dankert J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother. 2000 Aug;46(2):171–179. PubMed PMID: 10933638.
   PubMed Web of Science ®Google Scholar
• Yao ZW, Lu X, Shen C, et al. Comparison of flucytosine and fluconazole combined with amphotericin B for the treatment of HIV-associated cryptococcal meningitis: a systematic review and meta-analysis. Eur J Clin Microbiol Infect Dis. 2014 Aug;33(8):1339–1344. PubMed PMID: 24550039.
   PubMed Web of Science ®Google Scholar
• Limbird LE, Gilman AG. Goodman and Gilman’s the Pharmacological Basis of Therapeutics. New York: McGraw-Hill; 1996.
   Google Scholar
• Dodds ES, Drew RH, Perfect JR. Antifungal pharmacodynamics: review of the literature and clinical applications. Pharmacotherapy. 2000 Nov;20(11):1335–1355. PubMed PMID: 11079283.
   PubMed Web of Science ®Google Scholar
• Cloughesy TF, Landolfi J, Hogan DJ, et al. Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma. Sci Transl Med. 2016 Jun 1;8(341):341ra75. PubMed PMID: 27252174.
   PubMed Web of Science ®Google Scholar
• Cloughesy TF, Landolfi J, Vogelbaum MA, et al. Durable complete responses in some recurrent high grade glioma patients treated with Toca 511 & Toca FC. Neuro Oncol. 2018 May 12. PubMed PMID: 29762717. DOI:10.1093/neuonc/noy075
   Web of Science ®Google Scholar
• Mandel JJ, Cachia D, Liu D, et al. Impact of IDH1 mutation status on outcome in clinical trials for recurrent glioblastoma. J Neurooncol. 2016 Aug;129(1):147–154. PubMed PMID: 27270908; PubMed Central PMCID: PMCPMC5021066.
   PubMed Web of Science ®Google Scholar
• Husseini F, Delord JP, Fournel-Federico C, et al. Vectorized gene therapy of liver tumors: proof-of-concept of TG4023 (MVA-FCU1) in combination with flucytosine. Ann Oncol. 2017 Jan 1;28(1):169–174. PubMed PMID: 28177438.
   PubMed Web of Science ®Google Scholar
• Sahoo P, Frankel P, Ressler J, et al. Early changes in tumor perfusion from T1-weighted dynamic contrast-enhanced MRI following neural stem cell-mediated therapy of recurrent high-grade glioma correlate with overall survival. Stem Cells Int. 2018;2018:5312426. PubMed PMID: 29731779; PubMed Central PMCID: PMCPMC5872616.
   PubMedGoogle Scholar
• Kauffman CA, Frame PT. Bone marrow toxicity associated with 5-fluorocytosine therapy. Antimicrob Agents Chemother. 1977 Feb;11(2):244–247. PubMed PMID: 848928; PubMed Central PMCID: PMCPMC351961.
   PubMed Web of Science ®Google Scholar